What is Claimed is:

1. A pharmaceutical composition comprising a eutectic of 35%±2% by weight δ-mannitol ~~comprising~~ 65%±2% by weight Cyclobenzaprine HCl.

2. ~~The~~ A pharmaceutical composition ~~of claim 1,~~ comprising a eutectic of 65%±2% by weight ~~60% 90%~~ Cyclobenzaprine HCl and ~~40% 10%~~ 35%±2% by weight δ-mannitol, and a eutectic of 75%±2% by weight Cyclobenzaprine HCl and 25%±2% by weight β-mannitol.

3. The pharmaceutical composition of claim 1 or 2, wherein the eutectic of ~~comprising amounts of Cyclobenzaprine HCl and mannitol selected from: 60%±2% Cyclobenzaprine HCl and 40%±2% mannitol,~~ 35%±2% by weight δ-mannitol and 65%±2% by weight Cyclobenzaprine HCl melts at 134 °C±3 °C~~and 35%±2% mannitol, 70%±2% Cyclobenzaprine HCl and 30%±2% mannitol, 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol, 80%±2% Cyclobenzaprine HCl and 20%±2% mannitol, 85%±2% Cyclobenzaprine HCl and 15%±2% mannitol, and 90%±2% Cyclobenzaprine HCl and 10%±2% mannitol by weight~~.

~~4. The pharmaceutical composition of claim 3, comprising 75%±2% Cyclobenzaprine HCl and 25%±2% mannitol by weight.~~

~~5. The pharmaceutical composition of any one of claims 1-4, wherein the Cyclobenzaprine HCl:mannitol molar ratio is 1.76±0.1.~~

4~~6~~. The pharmaceutical composition of any one of claims 1-3~~5~~, wherein the Cyclobenzaprine HCl is micronized Cyclobenzaprine HCl.

5~~7~~. The pharmaceutical composition of any one of claims 1-4~~6~~, further comprising a basifying agent.

6~~8~~. The pharmaceutical composition of claim 5~~7~~, wherein the basifying agent is K_2HPO_4, Na_2PO_4 or anhydrous trisodium citrate.

~~9. The pharmaceutical composition of claim 7, wherein the basifying agent is Na_2HPO_4.~~

~~10. The pharmaceutical composition of claim 7, wherein the basifying agent is trisodium citrate, anhydrous.~~

7~~11~~. The pharmaceutical composition of any one of claims 1-6~~10~~, wherein said composition comprises granules.

8~~12~~. The pharmaceutical composition of claim 7~~11~~, wherein said granules comprise cyclobenzaprine HCl and mannitol.

9~~13~~. The pharmaceutical composition of claim 8~~12~~, wherein said mannitol is β--mannitol and δ--mannitol.

10~~14~~. The pharmaceutical composition of any one of claims 7-9~~11-13~~, wherein said granules comprise an inner layer comprising β--mannitol and an outer layer comprising the eutectic of δ-mannitol and Cyclobenzaprine HCl

11~~15~~. A method of manufacturing ~~a~~ the ~~eutectic~~ pharmaceutical composition of any one of claims 1-10~~14~~, comprising mixing Cyclobenzaprine HCl, ~~and~~ mannitol and a solvent.

12~~16~~. The method of claim 11~~15~~, wherein said mixing is wet granulation mixing.

13~~17~~. The method of claim 11~~15~~ or 12~~16~~, ~~further comprising~~ wherein the solvent is water, ~~mixing~~ an alcohol, or a mixture thereof. ~~with said Cyclobenzaprine HCl and said mannitol.~~

14~~18~~. The method of claim 13~~17~~, wherein said alcohol is methanol.

15~~19~~. The method of claim 13~~17~~, wherein said alcohol is ethanol.

16~~20~~. The method of any one of claims 12-15~~16-19~~, further comprising drying after said wet granulation.

17~~21~~. The method of claim 16~~20~~, wherein said wet granulation and drying are repeated one or more times.

18~~22~~. The method of any one of claims 12-15~~16-19~~, further comprising ~~crystallization~~ crystallizing the Cyclobenzaprine HCl-mannitol mixture after said wet granulation.

19~~23~~. The method of claim 18~~22~~, wherein said wet granulation and crystallization are repeated one or more times.

20~~24~~. A method of manufacturing the~~a eutectic~~ pharmaceutical composition according to ~~of~~ any one of claims 1-10~~14~~, comprising fluid bed drying Cyclobenzaprine HCl and mannitol in the presence of a solvent.

21. The method according to claim 20, wherein the solvent is water, an alcohol, or a mixture thereof.

~~25. The method of any one of claims 15-24, wherein the eutectic composition comprises β mannitol.~~

~~26. The method of claim 25, wherein the composition comprises Cyclobenzaprine HCl and the eutectic melts at 143.6±3 °C.~~

~~27. The method of any one of claims 15-24, wherein the eutectic composition comprises δ mannitol.~~

22~~28~~. The method of any one of claims 12-21~~-27~~, wherein the pharmaceutical composition comprises the eutectic of 35%±2% by weight δ-mannitol and 65%±2% by weight Cyclobenzaprine HCl and the eutectic melts at 134~~-°C~~±3 °C.